Post by
StockHawk1 on Jan 16, 2023 6:01pm
AGN on The Power Play to dicuss Phase 2b Ifenprodi study
Algernon Pharmaceuticals (AGN.c AGNPF) featured on The Power Play after announcing plans for a Phase 2b clinical study of their Ifenprodi drug for chronic cough. AGN plans to start the 180-patient 90-day study in Q3. Results from Phase 2a were promising, so this could be a big catalyst for AGN.